Oculis Holding AG (OCS)
13.05
-0.13
(-0.99%)
USD |
NASDAQ |
Aug 25, 15:49
Oculis Debt to Equity Ratio : 0.0116 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0116 |
| March 31, 2026 | 0.0114 |
| December 31, 2025 | 0.0118 |
| September 30, 2025 | 0.0189 |
| June 30, 2025 | 0.0072 |
| March 31, 2025 | 0.0068 |
| December 31, 2024 | 0.0161 |
| September 30, 2024 | 0.0131 |
| June 30, 2024 | 0.0119 |
| March 31, 2024 | 0.0075 |
| December 31, 2023 | 0.0065 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.0065 |
| June 30, 2023 | 0.0061 |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.0032 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Novartis AG | 1.180 |
| Roche Holding AG | -- |
| Addex Therapeutics Ltd. | 0.0311 |
| Sandoz Group AG | -- |
| Galderma Group AG | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 310.34M |
| Total Liabilities (Quarterly) | 38.43M |
| Shareholders Equity (Quarterly) | 271.91M |
| Current Ratio | 8.347 |
| Net Debt Paydown Yield | -0.04% |